SAILIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Sai Life Sciences disclosed its KPIs for Fiscal 2026, showing strong performance across all metrics. Revenue from operations grew to ₹21,924.92 million, a 29.38% YoY increase. EBITDA reached ₹6,529.47 million with a 29.78% margin, up from 15.07% in FY2022. PAT more than doubled to ₹3,489.10 million (105% YoY growth), with PAT margin expanding to 15.91% from just 0.72% four years ago. Operational efficiency improved significantly — Net Working Capital days fell from 204 to 86, and Inventory days dropped from 139 to 86. The company became nearly debt-free with Net Debt/Equity at 0.01x and Net Debt/EBITDA at 0.04x. ROCE improved to 18.23% from 3.21% in FY2022. Scientific staff count grew to 2,961 from 1,779. All KPIs were verified by Basethy & Joshi, Chartered Accountants.
The filing shows Sai Life Sciences has transformed into a highly profitable, asset-light business with strong cash generation. The consistent improvement in margins, working capital efficiency, and near-zero debt signals financial strength. The doubling of PAT and near 30% EBITDA margin make this an attractive update for investors.